BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 15249718)

  • 1. Phase I dose escalation study of carboplatin to a fixed dose of irinotecan as first-line treatment of small cell lung cancer.
    Schmittel A; Schulze K; Hütter G; Krebs P; Thiel E; Keilholz U
    Onkologie; 2004 Jun; 27(3):280-4. PubMed ID: 15249718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer.
    Okamoto H; Naoki K; Narita Y; Hida N; Kunikane H; Watanabe K
    Lung Cancer; 2006 Aug; 53(2):197-203. PubMed ID: 16781005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weekly irinotecan combined with carboplatin for patients with small-cell lung cancer: A phase I study.
    Ishimoto O; Sugawara S; Inoue A; Maemondo M; Nukiwa T
    Respir Investig; 2015 Jul; 53(4):156-60. PubMed ID: 26100175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
    Miller AA; Al Omari A; Murry DJ; Case D
    Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study.
    Briasoulis E; Golfinopoulos V; Karina M; Papakostas P; Pavlidis N; Fountzilas G
    Anticancer Drugs; 2010 Sep; 21(8):785-9. PubMed ID: 20647930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II and pharmacologic study of irinotecan and carboplatin for patients with lung cancer.
    Sato M; Ando M; Minami H; Ando Y; Ando M; Yamamoto M; Sakai S; Watanabe A; Ikeda T; Sekido Y; Saka H; Shimokata K; Hasegawa Y
    Cancer Chemother Pharmacol; 2001 Dec; 48(6):481-7. PubMed ID: 11800029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
    Johnson FM; Kurie JM; Peeples BO; Lee JJ; Feng L; Pisters KM; Fossella FV; Papadimitrakopoulou VA; Blumenschein GR; Komaki R; Glisson BS
    Clin Lung Cancer; 2003 Jul; 5(1):40-5. PubMed ID: 14596703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population-based maximum tolerated dose of irinotecan and carboplatin.
    Wild CA; Wang SE; Gandara DR; Lara PN; Meyers FJ; Tanaka M; Houston J; Lauder J; Lau DH
    Oncology (Williston Park); 2003 Jul; 17(7 Suppl 7):11-6. PubMed ID: 12886868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.
    Oshita F; Yamada K; Kato Y; Ikehara M; Noda K; Tanaka G; Nomura I; Suzuki R; Saito H
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):73-8. PubMed ID: 12750839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer.
    Sohn JH; Choi HJ; Chang J; Kim SK; Lee CG; Chung KY; Kim DJ; Cho BC; Shin SJ; Moon YW; Kim JH
    Lung Cancer; 2006 Dec; 54(3):365-70. PubMed ID: 17011068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer.
    Briasoulis E; Samantas E; Kalofonos H; Skarlos D; Makatsoris T; Christodoulou C; Fountzilas G; Bamias A; Dimopoulos MA; Kosmidis P; Pavlidis N
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):521-8. PubMed ID: 15959778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I trial of carboplatin and etoposide for elderly (>or=75 year-old) patients with small-cell lung cancer.
    Fukuda M; Soda H; Soejima Y; Fukuda M; Kinoshita A; Takatani H; Kasai T; Nagashima S; Kawabata S; Doi S; Kohno S; Oka M
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):601-6. PubMed ID: 16463061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
    Choong NW; Vokes EE; Haraf DJ; Tothy PK; Ferguson MK; Kasza K; Rudin CM; Hoffman PC; Krauss SA; Szeto L; Mauer AM
    J Thorac Oncol; 2008 Jan; 3(1):59-67. PubMed ID: 18166842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
    Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous chemoradiotherapy with irinotecan and cisplatin in limited disease small cell lung cancer: a phase I study.
    Klautke G; Fähndrich S; Semrau S; Büscher C; Virchow C; Fietkau R
    Lung Cancer; 2006 Aug; 53(2):183-8. PubMed ID: 16757061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial.
    Hermes A; Bergman B; Bremnes R; Ek L; Fluge S; Sederholm C; Sundstrøm S; Thaning L; Vilsvik J; Aasebø U; Sörenson S
    J Clin Oncol; 2008 Sep; 26(26):4261-7. PubMed ID: 18779613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers.
    Fukuda M; Oka M; Soda H; Terashi K; Kawabata S; Nakatomi K; Takatani H; Tsurutani J; Tsukamoto K; Noguchi Y; Fukuda M; Kinoshita A; Kohno S
    Clin Cancer Res; 1999 Dec; 5(12):3963-9. PubMed ID: 10632326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma.
    Okamoto H; Nagatomo A; Kunitoh H; Kunikane H; Watanabe K
    Cancer; 1998 Jun; 82(11):2166-72. PubMed ID: 9610696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I/II trial of irinotecan plus amrubicin supported with G-CSF for extended small-cell lung cancer.
    Harada T; Hamada A; Shimokawa M; Takayama K; Kudoh S; Maeno K; Saeki S; Miyawaki H; Moriyama A; Nakagawa K; Nakanishi Y
    Jpn J Clin Oncol; 2014 Feb; 44(2):127-33. PubMed ID: 24379211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer.
    Inoue A; Yamazaki K; Maemondo M; Suzuki T; Kimura Y; Kanbe M; Isobe H; Nishimura M; Saijo Y; Nukiwa T
    J Thorac Oncol; 2006 Jul; 1(6):551-5. PubMed ID: 17409916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.